Analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings per share (EPS) of ($0.26) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Amicus Therapeutics’ earnings. The lowest EPS estimate is ($0.33) and the highest is ($0.15). Amicus Therapeutics reported earnings per share of ($0.34) in the same quarter last year, which would indicate a positive year-over-year growth rate of 23.5%. The business is expected to report its next quarterly earnings results on Thursday, August 13th.
According to Zacks, analysts expect that Amicus Therapeutics will report full-year earnings of ($1.06) per share for the current year, with EPS estimates ranging from ($1.25) to ($0.94). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.85) to ($0.45). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Amicus Therapeutics.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.07). Amicus Therapeutics had a negative net margin of 155.73% and a negative return on equity of 63.24%. The company had revenue of $60.53 million for the quarter, compared to analysts’ expectations of $57.21 million.
Several research firms have recently weighed in on FOLD. JPMorgan Chase & Co. reissued a “buy” rating on shares of Amicus Therapeutics in a report on Monday, June 8th. BTIG Research began coverage on shares of Amicus Therapeutics in a report on Tuesday, June 16th. They set a “buy” rating and a $19.00 target price for the company. SVB Leerink reaffirmed a “market perform” rating and set a $19.00 target price on shares of Amicus Therapeutics in a report on Tuesday, May 19th. BidaskClub raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, Chardan Capital reaffirmed a “hold” rating and set a $12.50 target price on shares of Amicus Therapeutics in a report on Saturday, May 9th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Amicus Therapeutics presently has an average rating of “Buy” and a consensus price target of $19.08.
In related news, insider Jay Barth sold 30,000 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $15.51, for a total transaction of $465,300.00. Following the completion of the transaction, the insider now owns 193,204 shares in the company, valued at $2,996,594.04. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John F. Crowley sold 20,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $9.92, for a total transaction of $198,400.00. Following the transaction, the chief executive officer now owns 969,696 shares of the company’s stock, valued at approximately $9,619,384.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 169,785 shares of company stock valued at $2,071,121. Company insiders own 2.50% of the company’s stock.
Large investors have recently modified their holdings of the stock. Bank of Montreal Can boosted its position in shares of Amicus Therapeutics by 314.5% during the fourth quarter. Bank of Montreal Can now owns 93,398 shares of the biopharmaceutical company’s stock worth $910,000 after acquiring an additional 70,868 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Amicus Therapeutics by 3.6% during the fourth quarter. Bank of New York Mellon Corp now owns 2,255,081 shares of the biopharmaceutical company’s stock worth $21,965,000 after acquiring an additional 78,720 shares during the last quarter. State Street Corp boosted its position in shares of Amicus Therapeutics by 1.2% during the first quarter. State Street Corp now owns 11,129,151 shares of the biopharmaceutical company’s stock worth $102,833,000 after acquiring an additional 132,427 shares during the last quarter. Nuveen Asset Management LLC boosted its position in shares of Amicus Therapeutics by 92.8% during the fourth quarter. Nuveen Asset Management LLC now owns 4,154,771 shares of the biopharmaceutical company’s stock worth $40,468,000 after acquiring an additional 2,000,176 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its position in shares of Amicus Therapeutics by 18.3% during the first quarter. Parametric Portfolio Associates LLC now owns 192,799 shares of the biopharmaceutical company’s stock worth $1,781,000 after acquiring an additional 29,880 shares during the last quarter.
FOLD opened at $15.55 on Monday. The company has a quick ratio of 4.31, a current ratio of 4.45 and a debt-to-equity ratio of 0.50. The firm has a 50 day moving average price of $12.98 and a 200-day moving average price of $10.75. Amicus Therapeutics has a twelve month low of $6.25 and a twelve month high of $15.91. The stock has a market capitalization of $3.89 billion, a price-to-earnings ratio of -11.96 and a beta of 1.35.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Featured Story: What is Compound Interest?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.